-
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-10 Yuan Sun, Xu Wang, Wen‐Min Chen, Yue Hao, Ling‐Di Li, Jin‐Ying Li, Kai Sun, Zong‐Yan Shi, Hao Jiang, Qian Jiang, Xiao‐Jun Huang, Ya‐Zhen Qin
In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KITmut) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KITmut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KITmut (D816V/H/Y
-
Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-08 Elisabetta M. Abenavoli, Flavia Linguanti, Matilde Anichini, Vittorio Miele, Francesco Mungai, Marianna Palazzo, Luca Nassi, Benedetta Puccini, Ilaria Romano, Benedetta Sordi, Roberto Sciagrà, Gabriele Simontacchi, Alessandro M. Vannucchi, Valentina Berti
To recognize patients at high risk of refractory disease, the identification of novel prognostic parameters improving stratification of newly diagnosed Hodgkin Lymphoma (HL) is still needed. This study investigates the potential value of metabolic and texture features, extracted from baseline 18F‐FDG Positron Emission Tomography/Computed Tomography (PET) and Contrast‐Enhanced Computed Tomography scan
-
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-07 Maria Anele Romeo, Chiara Focaccetti, Andrea Arena, Rossella Benedetti, Michele Di Crosta, Camilla Palumbo, Maria Saveria Gilardini Montani, Roberta Santarelli, Roberta Gonnella, Gabriella D’Orazi, Roberto Bei, Mara Cirone
-
The role of baseline 2‐[18F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-06 Domenico Albano, Anna Calabrò, Francesco Dondi, Samuele Bagnasco, Alessandra Tucci, Francesco Bertagna
Diffuse Large B‐Cell Lymphomas (DLCBL) and mucosa‐associated lymphoid tissue (MALT) are the two most common primary gastric lymphomas (PGLs), but have strongly different features. DLBCL is more aggressive, is frequently diagnosed at an advanced stage and has a poorer prognosis. The aim of this retrospective study was to explore the role of fluorine‐18‐fluorodeoxyglucose positron emission tomography/computed
-
Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-01 Enrico Grande, Francesco Grippo, Claudio Barbiellini Amidei, Ugo Fedeli, Alberto Tosetto
-
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-28 Rong Wang, Yi Zhang, Jie Chang, Huafeng Wang, Yinjun Lou, Min Yang, Gaixiang Xu, Hongyan Tong, Wanzhuo Xie, De Zhou, Juying Wei, Wenyuan Mai, Xiujin Ye, Haitao Meng, Jie Jin, Hong‐Hu Zhu
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy (DAV) has shown safety and efficacy in eligible patients with newly diagnosed acute myeloid leukemia (AML). However, there are no direct comparisons between DAV and 3 + 7 daunorubicin and cytarabine chemotherapy (DA) alone. We performed a propensity score‐matched analysis to compare the outcomes of DAV group with historical DA group and
-
Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-28 João L. Pereira, Francisca Ferreira, Nuno R. dos Santos
Lymphomas are a heterogeneous group of diseases that originate from T, B or natural killer cells. Lymphoma treatment is based on chemotherapy, radiotherapy, and monoclonal antibody (mAb) or other immunotherapies. The P‐selectin glycoprotein ligand 1 (PSGL‐1) is expressed at the surface of hematological malignant cells and has been shown to have a pro‐oncogenic role in multiple myeloma and lymphoma
-
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-25 Andrea Duminuco, Antonella Nardo, Giuseppe A. Palumbo
-
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-25 Thierry Facon, Philippe Moreau, Ivan Špicka, Kenshi Suzuki, Kwee Yong, Joseph Mikhael, Taro Fukao, Kamlesh Bisht, Nicole M. Armstrong, Sandrine Macé, Marie‐Laure Risse, Thomas Martin
Gain/amplification of 1q21 (≥3 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti‐myeloma therapy and disease progression. In this updated subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285) in relapsed/refractory multiple myeloma (RRMM), we evaluated progression‐free survival (PFS)
-
Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-17 Lin-Ya Wang, Yao Li, Qian Jiang, Hao Jiang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Fei-Fei Tang
This study aimed to investigate the clinical characteristics and prognosis of Runt-related transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing the features of AML patients with or without RUNX1 mutation. We retrospectively analyzed 180 AML patients including 36 AML patients with mutant RUNX1(AML-RUNX1mut) and 144 AML patients with wild-type RUNX1(AML-RUNX1wt) were
-
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-16 Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, Giovanni Barosi, Pier Luigi Zinzani
Zanubrutinib has been approved for treating patients with different lymphoproliferative disorders and now represents a significant breakthrough in treating relapsed/refractory and previously untreated patients with chronic lymphocytic leukemia (CLL). Because few systematic studies or comparative randomized clinical trials have been conducted, optimal use of zanubrutinib in approved indications may
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-27
No abstract is available for this article.
-
Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-27 Marijana Virijevic, Nada Kraguljac-Kurtovic, Mirjana Mitrovic, Ljubomir Jakovic, Zoran Bukumuric, Nikola Pantic, Nikica Sabljic, Zlatko Pravdic, Mirjana Cvetkovic, Vesna Knezevic, Tijana Dragovic-Ivancevic, Irena Djunić, Jovan Rajic, Violeta Milosevic, Milena Todorovic-Balint, Ana Vidovic, Nada Suvajdzic-Vukovic
Examination of central nervous system (CNS) involvement is not routine diagnostic practice in adult patients with acute myeloid leukemia (AML). Therefore, many asymptomatic patients with CNS involvement might go undetected. The effect of CNS involvement on the AML disease course is not well defined, with conflicting results regarding clinical outcome. This study aimed to determine the incidence of
-
ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-12 Zong-Yan Shi, Xu Wang, Wen-Min Chen, Ling-Di Li, Yue Hao, Jin-Ying Li, Kai Sun, Xiao-Su Zhao, Hao Jiang, Qian Jiang, Xiao-Jun Huang, Ya-Zhen Qin
Zinc finger protein 384 (ZNF384) rearrangement defined a novel subtype of B-cell acute lymphoblastic leukemia (B-ALL). The prognostic significance of ZNF384 fusion transcript levels represented measurable residual disease remains to be explored. ZNF384 fusions were screened out in 57 adult B-ALL patients at diagnosis by real-time quantitative polymerase chain reaction and their transcript levels were
-
Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-05 Taku Fujimura, Kentaro Ohuchi, Tetsuya Ikawa, Yumi Kambayashi, Ryo Amagai, Sadanori Furudate, Yoshihide Asano
Mycosis fungoides (MF) progresses slowly before advancing to skin tumors followed by lymph node and visceral involvement. Among MF progression, stage IIB is an initial time point of tumor formation in MF. Since MF in tumor stage possess abundant blood vessels, it is important to evaluate the pro-angiogenic factors before and after MF in stage IIB. In this report, we investigated pro-angiogenic soluble
-
Diagnosis of chronic B-cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-05 Zofia Gross, Richard Veyrat-Masson, Béatrice Grange, Sarah Huet, Aurélie Verney, Alexandra Traverse-Glehen, Philippe Ruminy, Lucile Baseggio
Flow cytometry (FCM) has become a method of choice for immunologic characterization of chronic lymphoproliferative disease (CLPD). To reduce the potential subjectivities of FCM data interpretation, we developed a machine learning random forest algorithm (RF) allowing unsupervised analysis. This assay relies on 16 parameters obtained from our FCM screening panel, routinely used in the exploration of
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-03
No abstract is available for this article.
-
Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-12-21 M. Picardi, C. Giordano, N. Pugliese, M. Mascolo, S. Varricchio, G. Troncone, E. Vigliar, C. Bellavicine, M. Lamagna, D. Lisi, A. Vincenzi, F. Pane
Tumor-infiltrating macrophages (TIMs) are constantly ≥5% staining at immunohistochemical analysis on biopsy specimens of tumor masses, in primary mediastinal large B-cell lymphoma (PMBL) and mediastinal gray zone lymphoma (MGZL).1-3 The presence of many CD68-positive TIMs into lymph node microenvironment of both PMBL and MGZL is associated with shortened progression-free survival (PFS) following conventional
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2023-12-10
No abstract is available for this article.
-
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021 Hematol. Oncol. (IF 3.3) Pub Date : 2023-12-06 Jakob R. Passweg, Helen Baldomero, Marc Ansari, Caroline Arber, Yves Chalandon, Michael Daskalakis, Miriam Diepold, Tamara Diesch-Furlanetto, Michel A. Duchosal, Sabine Gerull, Tayfun Güngör, Dominik Heim, Felicitas Hitz, Andreas Holbro, Stavroula Masouridi-Levrat, Gayathri Nair, Urban Novak, Thomas Pabst, Christoph Renner, Georg Stussi, Dominik Schneidawind, Urs Schanz, Luciano Wannesson, Jörg P.
The Swiss Blood Stem Cell Transplantation and Cellular Therapy Group (SBST) leads a mandatory national registry for all hematopoietic stem cell transplants (HCT) and cellular therapies. After 25 years, information was available for 11,226 patients receiving an HCT (4031 allogeneic and 7195 autologous), including 925 pediatric patients. We compared patient characteristics and outcome by quinquennia
-
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry Hematol. Oncol. (IF 3.3) Pub Date : 2023-12-04 Pellegrino Musto, Jon Salmanton-García, Nicola Sgherza, Rui Bergantim, Francesca Farina, Andreas Glenthøj, Guldane Cengiz Seval, Barbora Weinbergerová, Valentina Bonuomo, Yavuz M. Bilgin, Jaap van Doesum, Ozren Jaksic, Benjamín Víšek, Iker Falces-Romero, Monia Marchetti, Julio Dávila-Valls, Sonia Martín-Pérez, Marcio Nucci, Alberto López-García, Federico Itri, Caterina Buquicchio, Luisa Verga, Klára
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general
-
Classic Hodgkin lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-12-01 Justine Kahn, Bouthaina Dabaja, Susan Wu, Kara Kelly, Leanne Berkahn, Astrid Pavlovsky, Anna Sureda, Ann LaCasce
Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5-year overall survival
-
Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T-cell lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-11-16 Daniel Aires, Sunil Abhyankar
Patients with cutaneous T-cell lymphoma with progressive disease typically undergo a series of skin-directed and systemic therapy regimens during cycles of response and relapse. Extracorporeal photopheresis (ECP) is an effective and safe systemic treatment option, often reserved for later stages of disease and typically employed after failure of several other therapies. ECP has benefits in response
-
A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-11-09 Pablo Mozas, Sebastian Casanueva-Eliceiry, Andrea Rivero, Ángel Serna, Marc Simó, Sonia Rodríguez, Alfredo Rivas-Delgado, Ferran Nadeu, Juan Gonzalo Correa, Juan Antonio Piñeyroa, Amanda Isabel Pérez-Valencia, Katia Guinetti-Ortiz, Marta Gómez-Hernando, Eva Giné, Julio Delgado, Neus Villamor, Elías Campo, Laura Magnano, Pau Abrisqueta, Xavier Setoain, Armando López-Guillermo
Watchful waiting is an acceptable management strategy for advanced-stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment-free observation period will last remains imperfect. We explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters were predictive of time to first treatment (TTFT). We
-
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions Hematol. Oncol. (IF 3.3) Pub Date : 2023-11-08 Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack
In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for CLL, do not directly target p53 or restore its disrupted pathway. Consequently, resistance to therapy and unfavorable clinical outcomes often accompany
-
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma? Hematol. Oncol. (IF 3.3) Pub Date : 2023-11-08 Carmen de Ramon Ortiz, Sisi Wang, Anastasios Stathis, Francesco Bertoni, Thorsten Zenz, Urban Novak, Federico Simonetta
About one third of patients with diffuse large B-cell lymphoma (DLBCL) have a relapsing/refractory (R/R) disease after first line chemo-immunotherapy, with particularly poor outcomes observed in patients with primary refractory disease and early relapse. CD19 specific chimeric antigen receptor (CAR) T cell therapy is a game changer that results in durable and complete response rates in almost half
-
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-11-06 Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Takao Miwa, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Michio Sawada, Hisashi Tsurumi, Masahito Shimizu
This study evaluated the efficacy and safety of salvage chemotherapy with gemcitabine, carboplatin, dexamethasone, and rituximab (GCD ± R) for Japanese patients with relapsed or refractory non-Hodgkin lymphoma (NHL). A multicenter, phase II trial of GCD ± R administered every 3 weeks for up to 6 cycles was conducted. Rituximab was administered as a therapeutic strategy for CD20-positive lymphoma. The
-
Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-24 Kang Le, Jordan Vollenweider, JingJing Han, Nicholas Staudinger, Mary Stenson, Lara Bayraktar, Linda E. Wellik, Matthew J. Maurer, Ellen D. McPhail, Thomas E. Witzig, Mamta Gupta
Peripheral T-cell lymphoma (PTCL) is a clinically heterogeneous group that represents 10%–15% of all lymphomas. Despite improved genetic and molecular understanding, treatment outcomes for PTCL have not shown significant improvement. Although Janus kinase-2 (JAK2) plays an important role in myeloproliferative neoplasms, the critical role of JAK isoforms in mediating prosurvival signaling in PTCL cells
-
Tagraxofusp in myeloid malignancies Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-17 Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna, Massimo Gentile
Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-08
No abstract is available for this article.
-
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-05 Hazim S. Ababneh, Andrea K. Ng, Jeremy S. Abramson, Jacob D. Soumerai, Ronald W. Takvorian, Matthew J. Frigault, Chirayu G. Patel
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) parameters on the CAR T-related outcomes and toxicities are limited. Therefore
-
Expression of “DNA damage response” pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-05 Adnan Mansoor, Hamza Kamran, Hassan Rizwan, Ariz Akhter, Tariq Mahmood Roshan, Meer-Taher Shabani-Rad, Prashant Bavi, Douglas Stewart
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are two of the most prevalent non-Hodgkin's lymphoma subtypes. Despite advances, treatment resistance and patient relapse remain challenging issues. Our study aimed to scrutinize gene expression distinctions between DLBCL and FL, employing a cohort of 53 DLBCL and 104 FL samples that underwent rigorous screening for genetic anomalies
-
Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-04 Yigeng Cao, Xinhui Zheng, Haixiao Zhang, Mingyang Wang, Wenwen Guo, Xin Chen, Weihua Zhai, Jialin Wei, Donglin Yang, Yong Huang, Aiming Pang, Sizhou Feng, Erlie Jiang, Mingzhe Han
Recurrence following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the major cause of treatment failure in patients with myeloid malignancy. Azacytidine (AZA) maintenance is a promising therapy to prevent relapse and improve survival. We conducted a prospective, one-arm study involving 78 patients with myeloid malignancy at a high risk of recurrence who were enrolled between September
-
Correction to Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105 Hematol. Oncol. (IF 3.3) Pub Date : 2023-10-04
Suzuki T, Maruyama D, Machida R, et al. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105. Hematol Oncol. 2023;41(3):590–593. https://doi.org/10.1002/hon.3103. Subsequent to the publication of above article, the authors noted that
-
Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-30 Ying Zhang, Hongzhi Geng, Liangyu Zeng, Jiaqi Li, Qin Yang, Sixun Jia, Xiangping Zong, Wenzhi Cai, Shuangzhu Liu, Yutong Lu, Lei Yu, Caixia Li, Depei Wu
Dual-targeted chimeric antigen receptor T (CAR-T) cell is an important strategy to improve the efficacy of CD19 CAR-T cell against refractory or relapsed B cell non-Hodgkin lymphoma (R/R B-NHL). However, durable responses are not achieved in most patients, in part owing CAR-T cell exhaustion caused by PD-1/PD-L1 pathway. We conducted a prospective, single-arm study of dual-targeted CD19/22 CAR-T cell
-
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-29 Paolo Sportoletti, Luca Laurenti, Annalisa Chiarenza, Gianluca Gaidano, Elisa Albi, Francesca Romana Mauro, Livio Trentin, Daniele Vallisa, Fabrizio Pane, Antonio Cuneo, Francesco Albano, Giulia Zamprogna, Marta Coscia, Alessandro Gozzetti, Gianluigi Reda, Morena Caira, Paola Finsinger, Giuliana Gualberti, Emilia Iannella, Simona Malgieri, Stefano Molica
Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatment line, and socio-demographic characteristics in a cross sectional, observational study conducted at 16 Italian hematology centers. Study visits occurred between
-
Comparison of autologous, matched sibling, and alternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-26 Mingyang Wang, Haixiao Zhang, Xinhui Zheng, Jia Liu, Jiali Wang, Yigeng Cao, Xiaoyu Zhang, Rongli Zhang, Xin Chen, Weihua Zhai, Qiaoling Ma, Jialin Wei, Yong Huang, Donglin Yang, Yi He, Aiming Pang, Sizhou Feng, Mingzhe Han, Erlie Jiang
Autologous hematopoietic stem cell transplantation (auto-HSCT), matched sibling donor HSCT (MSD-HSCT), and alternative donor HSCT (AD-HSCT) are viable post-remission treatment options for acute myeloid leukemia (AML). A total of 283 de novo favorable- and intermediate-risk AML patients, based on the ELN 2022 criteria, in first complete remission were initially included for propensity score matching
-
A short report of novel acute promyelocytic leukemia with runt-related transcription factor 1-retinoic acid receptor alpha. Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-26 Xin Kong,Mingming Hu,Jian Zhang,Jingjing Han,Yin Liu,Baoquan Song,Zhihong Lin,Huiying Qiu
-
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-23 Mohamed Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Benjamin Engelhardt, Eva Doelger, Weize Huang, Edyta Dobkowska, Shaji Kumar, Rajeev M. Menon, Ahmed Hamed Salem
Venetoclax, a potent BCL-2 inhibitor, is currently under development for treatment of t(11;14) Multiple myeloma (MM). The objective of this research was to investigate the exposure–response relationships of venetoclax for a phase 1/2 study evaluating venetoclax monotherapy or in combination with dexamethasone in relapsed or refractory MM. A total of 117 patients receiving venetoclax at 300, 600, 800
-
Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-20 Takayuki Sakuma, Shin Fujisawa, Masatsugu Tanaka, Maki Hagihara, Hiroyuki Fujita, Katsumichi Fujimaki, Kengo Katsuki, Masahiro Akimoto, Marika Tanaka, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Takuya Miyazaki, Takayoshi Tachibana, Kenji Matsumoto, Rika Sakai, Heiwa Kanamori, Hideaki Nakajima
The CFA ratio, calculated using pretreatment C-reactive protein (CRP), fibrinogen, and albumin levels (CRP × fibrinogen/albumin), was previously reported to be a significant prognostic factor for acute myeloid leukemia (AML). This multicenter retrospective study evaluated the prognostic value of the CFA ratio in 328 adult patients with newly diagnosed AML from April 2000 to March 2018. The median age
-
Thymocyte selection-associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-15 Haiyue Niu, Mengying Zhang, Mengyuan Liu, Liyan Yang, Liping Yang, Jie Ren, Yating Yu, Yumei Liu, Limin Xing, Zonghong Shao, Huaquan Wang
Myelodysplastic syndromes (MDS) patients often experience CD8+T lymphocytes exhaustion, which plays a crucial role in the development of MDS. However, the specific role of thymocyte selection-associated high mobility box protein (TOX) in the CD8+T lymphocytes exhaustion in MDS patients remains unclear. In this study, we investigated the role of TOX in CD8+T lymphocytes exhaustion in patients with MDS
-
PAQR3 facilitates the ferroptosis of diffuse large B-cell lymphoma via the regulation of LDLR-mediated PI3K/AKT pathway Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-10 Xiangxiang Song, Weiming Zhang, Nasha Yu, Xing Zhong
Progesterone and adiponectin receptor 3 (PAQR3) has been found to regulate tumor progression by mediating cell ferroptosis. However, whether PAQR3 mediates ferroptosis in diffuse large B-cell lymphoma (DLBCL) needs further investigation. The mRNA and protein levels of PAQR3 and low-density lipoprotein receptor (LDLR) were assessed by qRT-PCR and WB assays. Cell proliferation was detected by MTT assay
-
Reducing the risks of nuclear war—The role of health professionals Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-14 Kamran Abbasi, Parveen Ali, Virginia Barbour, Kirsten Bibbins-Domingo, Marcel G. M. Olde Rikkert, Richard Horton, Robert Mash, Carlos Monteiro, Elena N. Naumova, Eric J. Rubin, Peush Sahni, James Tumwine, Paul Yonga, Chris Zielinski, Arun Mitra, Tilman Ruff, Andy Haines, Ira Helfand
In January 2023, the Science and Security Board of the Bulletin of the Atomic Scientists moved the hands of the Doomsday Clock forward to 90 s before midnight, reflecting the growing risk of nuclear war.1 In August 2022, the UN Secretary-General António Guterres warned that the world is now in “a time of nuclear danger not seen since the height of the Cold War.2 The danger has been underlined by growing
-
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy. Hematol. Oncol. (IF 3.3) Pub Date : 2023-09-07 Hazim S Ababneh,Matthew J Frigault,Chirayu G Patel
-
Identifying and addressing unmet clinical needs in primary cutaneous B-cell lymphoma: A consensus-based paper from an ad-hoc international panel Hematol. Oncol. (IF 3.3) Pub Date : 2023-08-30 Pietro Quaglino, Nicola Pimpinelli, Pier Luigi Zinzani, Marco Paulli, Stefano Pileri, Emilio Berti, Lorenzo Cerroni, Joan Guitart, Youn H. Kim, Serena Rupoli, Marco Santucci, Gabriele Simontacchi, Maarten Vermeer, Richard Hoppe, Barbara Pro, Steven H. Swerdlow, Giovanni Barosi
Primary cutaneous B-cell lymphomas (PCBCLs) are lymphoproliferative disorders that appear on the skin without evidence of extracutaneous manifestations at the time of diagnosis. There is a lack of evidence-based guidelines for their clinical management due to the availability of very few large scale studies and controlled clinical trials. Here we present and discuss a series of major unmet clinical
-
Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy Hematol. Oncol. (IF 3.3) Pub Date : 2023-08-18 Takaaki Konuma, Hidehiro Itonaga, Yoshimitsu Shimomura, Machiko Fujioka, Kazunari Aoki, Naoyuki Uchida, Makoto Onizuka, Atsushi Jinguji, Masatsugu Tanaka, Yasunori Ueda, Yuta Katayama, Masashi Sawa, Haruyuki Tanaka, Hirohisa Nakamae, Toshiro Kawakita, Yumiko Maruyama, Satoshi Takahashi, Fumihiko Ishimaru, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potential curative therapeutic modality for advanced myelodysplastic syndrome (MDS). Within HCT, the advancement of cord blood transplantation (CBT) procedures has resulted in a drastic expansion of CBT as a donor source for MDS. However, data comparing matched sibling donors (MSDs) HCT with CBT for advanced MDS, which was defined
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2023-08-09
No abstract is available for this article.
-
Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax Hematol. Oncol. (IF 3.3) Pub Date : 2023-08-07 Tamara Mateu-Albero, Ana Marcos-Jimenez, Pablo Delgado-Wicke, Fernando Terrón, Javier Loscertales, José María Serra López-Matencio, Cecilia Muñoz-Calleja, Carlos Cuesta-Mateos
The Bruton's tyrosine kinase inhibitor ibrutinib and the B-cell lymphoma 2 anti-apoptotic protein inhibitor venetoclax provide high response rates in chronic lymphocytic leukemia (CLL). However, there is a growing number of patients that relapse after treatment or show refractory disease, thus new targets and agents are still needed. We have previously reported the chemokine receptor CCR7 as a relevant
-
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition? Hematol. Oncol. (IF 3.3) Pub Date : 2023-08-03 Cosimo Cumbo, Paola Orsini, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Vincenzo Tragni, Nicoletta Coccaro, Giuseppina Tota, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Crescenzio Francesco Minervini, Angela Minervini, Immacolata Attolico, Mattia Gentile, Ciro Leonardo Pierri, Giorgina Specchia, Pellegrino Musto, Francesco Albano
TNFRSF13B mutations are widely associated with common variable immunodeficiency. TNFRSF13B was recently counted among relevant genes associated with childhood-onset of hematological malignancies; nonetheless, its role in acute myeloid leukemia (AML) remains unexplored. We report the study of a family with two cases of AML, sharing a germline TNFRSF13B mutation favoring the formation of a more stable
-
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-26 Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Michael Stouffs, Peter Langmuir, Juan-Manuel Sancho
Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit with monotherapy in a phase 2 study in relapsed or refractory (R/R) follicular lymphoma (FL). CITADEL-102 (NCT03039114), a phase 1, multicenter study, assessed the efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with R/R FL. Patients were ≥18 years of age with histologically
-
Magnesium enhances the graft-versus-tumor effect of donor lymphocytic infusion on hematologic malignancies Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-26 Yan Wei, Jiayuan Guo, Ning Lu, Yi Liu, Lijun Wang, Lili Wang, Jian Bo, Honghua Li, Liping Dou, Daihong Liu, Chunji Gao
Donor lymphocyte infusion (DLI) cures relapsed hematologic malignancies after allogeneic hematopoietic stem cell transplantation through the graft-versus-tumor (GVT) effect. Although the important role of magnesium in enhancing immunity has been mentioned in studies, limited clinical data have explored how magnesium affects the efficacy of DLI. Besides, although laboratory data demonstrate that magnesium
-
Personalised therapy in follicular lymphoma – is the dial turning? Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-22 Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne-Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%–25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment
-
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-17 Karima Amaador, Catherine Thieblemont, Judith Trotman, Monique C. Minnema
Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies
-
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-15 Zeno Pasquini, Alice Toschi, Beatrice Casadei, Cinzia Pellegrini, Alessandra D’Abramo, Serena Vita, Alessia Beccacece, Linda Bussini, Maria Clara Chionsini, Nicola Dentale, Alessia Cantiani, Tiziana Lazzarotto, Michele Bartoletti, Emanuele Nicastri, Pierluigi Zinzani, Maddalena Giannella, Pierluigi Viale
Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID-19-associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection. We report a case series of adult patients with B cell malignancies and/or undergoing B cell targeting therapies with persisting SARS-CoV-2 infection and treated with a combination
-
Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-15 Camille Perroud, Dario Thurian, Martin Andres, Arnaud Künzi, Gertrud Wiedemann, Sacha Zeerleder, Ulrike Bacher, Thomas Pabst, Yara Banz, Naomi Porret, Ekaterina Rebmann
Until now, next generation sequencing (NGS) data has not been incorporated into any prognostic stratification of multiple myeloma (MM) and no therapeutic considerations are based upon it. In this work, we correlated NGS data with (1) therapy response and survival parameters in newly diagnosed multiple myeloma, treated by VRd * and (2) MM disease stage: newly diagnosed multiple myeloma (ndMM) versus
-
Pixantrone as bridging therapy to allogeneic transplantation or in CAR T-cell pathway in patients with diffuse large B-cell lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-13 Ginevra Lolli, Lisa Argnani, Guido Gini, Beatrice Casadei, Cinzia Pellegrini, Monica Tani, Eleonora Prete, Michele Cimminiello, Francesca Bonifazi, Pier Luigi Zinzani
Not due for a Letter (as per Editor/Reviewers suggestion the initial original article was changed in a Letter)
-
The course of patients with hairy cell leukemia during the omicron surge of the Covid-19 pandemic Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-13 Tamar Tadmor, Guy Melamed, Tal Patalon, Hilel Alapi, Lior Rokach
In this study, we aim to explore the outcomes of Covid-19 infection in patients with Hairy cell leukemia (HCL). The cohort is based on data obtained from electronic medical records. It includes 218 consecutive patients diagnosed with HCL between 16 June 1998, and 20 September 2022, out of which the coronavirus has infected 85 patients during the Omicron surge. Out of 85 patients with HCL who were infected
-
Diffuse large B-cell lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-12 Allison Barraclough, Eliza Hawkes, Laurie H. Sehn, Sonali M. Smith
Large B-cell lymphoma, the prototype of aggressive non-Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma-related deaths. For nearly 4 decades, the goal of treatment has been “cure”, first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and subsequently with rituximab plus CHOP. However, there is significant clinical, pathologic
-
Ultrasonography-guided core-needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front-line biopsies in a multicenter Italian study Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-06 Marco Picardi, Claudia Giordano, Elena Vigliar, Pio Zeppa, Imma Cozzolino, Novella Pugliese, Roberta Della Pepa, Maria Esposito, Davide Pio Abagnale, Mauro Ciriello, Giada Muccioli-Casadei, Giancarlo Troncone, Daniela Russo, Massimo Mascolo, Silvia Varricchio, Rossella Accarino, Marcello Persico, Fabrizio Pane
The reliability and safety of front-line ultrasonography guided core needle biopsy (UG-CNB) performed with specific uniform approach have never been evaluated in a large series of patients with lymphadenopathies suspected of lymphoma. The aim of this study was to assess the overall accuracy of UG-CNB in the lymph node histological diagnosis, using a standard reference based on pathologist consensus
-
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime Hematol. Oncol. (IF 3.3) Pub Date : 2023-07-05 Osnat Bairey, Eyal Lebel, Chen Buxbaum, Tzvika Porges, Alisa Taliansky, Ronit Gurion, Neta Goldschmidt, Tzahala Tzuk Shina, Miri Zektser, Liron Hofstetter, Tali Siegal
Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rare disease may yield information that might prove useful for the future design of randomized clinical trials. We retrospectively analyzed the data of 222 newly diagnosed PCNSL